1. Volume 74, Issue 6, Pages 782-790 (September 2008)
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease 
Sai Ram Keithi-Reddy, Francesco Addabbo, Tejas V. Patel, Bharati V. Mittal, Michael S. Goligorsky, Ajay K. Singh 
Kidney International 
Volume 74, Issue 6, Pages (September 2008)
DOI: /ki
Copyright © 2008 International Society of Nephrology Terms and Conditions

2. Figure 1
Number of anemic patients and patients on ESAs by tertiles of CRP in CKD cohort. Among anemic subjects, 35.9% were in the third tertile whereas 33% were in the first tertile for CRP (Mantel–Haenszel test for linear association; P=0.58) (a). Fifty percentage of the anemic subjects on ESAs were in the third tertile whereas 33% of epo-naive patients were in the third tertile for CRP (Mantel–Haenszel test for linear association; P=0.013). Patients in the first and third tertiles were compared for P-value (b). CKD, chronic kidney disease; CRP, C-reactive protein; ESAs, erythropoiesis-stimulating agents.
Kidney International  , DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

3. Figure 2
Odds ratios for upper two quartiles for patients treated with ESAs. In all, 71.4% of the patients on ESAs were in upper two quartiles for IL-6 compared to 51.9% of ESA-naive anemic and 40.4% of non-anemic patients with unadjusted odds of 3.6 (a). In all, 76.2% of the patients on ESAs were in upper two quartiles for IL-8 compared to 59.3% of ESA-naive anemic and 34.6% of non-anemic patients with unadjusted odds of 6.0 (b). In total, 71.4% of the patients on ESAs were in upper two quartiles for TNF-α compared to 55.6% of ESA-naive anemic and 38.5% of non-anemic patients with unadjusted odds of 4.0 (c). Sixty percentage of the patients on ESAs were in the upper two quartiles for Ferritin compared to 44% of ESA-naive anemic and 48.9% of non-anemic patients with unadjusted odds of 1.5 (d). A total of 61.9% of the patients on ESAs were in the lower two quartiles for albumin compared to 77.8% of ESA-naive anemic and 34.6% of non-anemic patients with unadjusted odds of 6.0 (e). Odds ratios are for the use of ESAs. *Lower two and upper two quartiles are represented in reverse order for the convenience of readers. ESAs, erythropoiesis-stimulating agents; IL, interleukin; TNF-α, tumor necrosis factor-α.
Kidney International  , DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions